Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Bayer
Sponsor:
Collaborator:
Hamilton Health Sciences Corporation, Population Health Research Institute
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01776424
First received: January 24, 2013
Last updated: November 17, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2018
  Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)